Home Archives 2012 January

Monthly Archives: January 2012

The convergence of ubiquitous smartphones, wireless Internet, and low-cost monitoring devices, is driving the emergence of a new world of digital health. At the same time, cost pressures on healthcare are creating demand for new ways to not just improve the way patients receive information and care and the way doctors provide it, but fundamentally change the way they interact with each other. The article discusses a venture capitalist's approach to investing in the sector.


 

Full details at the Journal of Commercial Biotechnology

In keeping with an emerging literature on the role of business education in the development of entrepreneurially-intentioned biotechnologists, this paper describes the actions and experiences of an entrepreneurship program that began in the late 1990’s. Along the way it illustrates how a business-centric approach can shift the budding entrepreneur’s perspective from a product to a market orientation when considering an innovation’s commercialization. While the developmental timeline and specific stages of the adoption process for biotechnology-based products vary from traditional consumer or industrial products, there many similarities, foremost is the notion that to be successful the market must perceive significant advantage to the new offering. Lastly, this paper provides thoughts on potentially profitable areas for program expansion and new foci, especially regarding the globalization of biotechnology innovation and international opportunities.

Full details at the Journal of Commercial Biotechnology

There is a wide body of literature on biotechnology clusters. However, most of the works has been focused on the description of the clusters as well as the development of biotechnology clusters in USA, Europe and other developed countries. Much less attention has been paid to the development of biotechnology clusters in developing countries. The aim of this paper is to gain a better understanding of the emergence of biotechnology clusters in Egypt and South Africa.

Full details at the Journal of Commercial Biotechnology

Collaborations focusing on innovation are often born with the conception of a technology, typically as a result of one side’s research effort. Collaborations for innovation can also be made through a deliberate process of identifying strategic synergies that should, with appropriate incentives, lead to jointly created technology in the selected area of interest.
The predominant factors motivating the parties to collaborate will heavily influence the agreement structure selected to support the collaboration. If a specific technology was “born” prior to the collaboration, the parties will most likely memorialize their collaboration in an agreement specific to the joint development and commercialization for that technology. In contrast, when the parties are entering the collaboration to stimulate innovation, the agreement is often structured as a master agreement.
Regardless of the agreement structure, there are two keys to a successful collaboration for innovation: (1) effective communication; and (2) balancing incentives. Full details at the Journal of Commercial Biotechnology

The debates over the Obama Administration’s health care reform law, and, more recently, the federal budget deficit and national debt have focused attention on the growth in costs of the Medicare program.  Three approaches to reducing Medicare expenditures command the most attention.  Under the first, changes to the Medicare delivery system – such as accountable care organizations (ACOs) and medical homes – are believed to have the potential to reduce the growth in costs in the program over time.  Under the second, tinkering with the reimbursement formulae in the Medicare program – pejoratively, government “price fixing” – will reduce the price that Medicare pays for an item or service, thereby reducing the growth in costs.  A third approach – converting Medicare to a premium support or defined contribution model – has been passed by the House of Representatives, but has failed in the United States Senate.

This article addresses the effect of these various approaches on Medicare payment for outpatient prescription drugs and biotechnology products.  It begins by analyzing the Administration’s ACO regulation and the effect that this regulation may have on reimbursement for outpatient prescription drugs and biotechnology products.  It then addresses legislative proposals to alter the Medicare reimbursement formulae for these products.  It concludes by speculating on how the Medicare reform legislation passed by the House of Representatives might affect reimbursement for outpatient prescription drugs and biotechnology products.

Full details at the Journal of Commercial Biotechnology

An increasing number of chemicals and materials, like base chemicals and polymers, as well as high value products, such as consumer chemicals and specialty chemicals, are produced using biotechnology in one or more of the process steps. In 2010, the sale volume of biotechnology products was around 92 billion Euro worldwide. Sales are estimated to increase to around 228 billion Euro in 2015 and to around 515 billion Euro in 2020. On a sector level, the largest market potential lies in the production of biopolymers and active pharmaceutical ingredients. As a rule, commercial development is mainly driven by multinational enterprises, whereas small and medium enterprises contribute primarily to the technological development. Especially the latter group faces several challenges during their development. These mainly concern business models and growth strategies as well as financing strategies and resources. Investors have not yet fully identified the area of industrial biotechnology as an attractive investment field but they could become a major capital source as they start to understand more the potential of industrial biotechnology. Full details at the Journal of Commercial Biotechnology